Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Sarcoma surgery at Gustave Roussy
3 questions to Dr Charles Honoré, head of sarcoma surgery at Gustave Roussy
Published on
Changed on
3 questions to Dr Charles Honoré, head of sarcoma surgery at Gustave Roussy
What are the features of sarcoma surgery?
These rare malignant tumours develop from connective and support tissues. Each year they affect more than 4,000 people in France. Their locations are extremely varied and more than 50 different sub-types exist, capable of appearing at any age, including in children. In general, this disease is poorly understood though it requires very specific management, notably surgical, in which practitioner expertise is essential.
Gustave Roussy is one of three expert coordinating centres at the national level for sarcomas. What does this mean?
We are the institution which treats the most patients. We have a team of specialists, all experts in this field. In the case of certain tumour locations, we maintain a close collaboration with our partners at the Bicêtre CHU and at the Marie-Lannelongue du Plessis-Robinson medico-surgical Centre. Moreover, we provide consultative assistance to all our colleagues in order to assure patients of the best possible management, wherever they may be.
What are the prospects regarding your activities?
Our surgical projects pursue three main lines: research, both clinical and fundamental, with several projects involving rare complex tumours; training which, in the field of sarcomas, is still in its infancy in France; and patient care, with notably the development of a “day centre” as well as early rehabilitation programmes and mini-invasive robotic surgery for certain selected indications.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
